Searchable abstracts of presentations at key conferences in endocrinology

ea0002oc23 | Growth Regulation | SFE2001

Pituitary Tumour Shrinkage During Treatment of Acromegaly with Sandostatin LAR

Jenkins P , Yeo P , Besser G , Evanson J , Monson J

Transsphenoidal surgery results in biochemical cure of approximately 50% of all acromegalic patients, depending on tumour size and surgical expertise. It is uncertain whether prior treatment with somatostatin analogues would result in tumour shrinkage and therefore improve the efficacy of subsequent surgery. Aims: To determine whether 6 months de novo treatment with Sandostatin LAR results in tumour shrinkage. Methods: 6 patients (mean age 53 yr; range 42-...

ea0009p103 | Endocrine tumours and neoplasia | BES2005

Peripituitary tumour surveillance imaging in patients receiving growth hormone replacement

Chung T , Evanson J , Besser G , Chew S , Grossman A , Monson J , Drake W

Introduction: Growth hormone (GH) replacement is widely used in the management of patients with adult-onset (AO) GH deficiency (GHD). In most cases, AO-GHD arises as a result of pituitary/peri-pituitary tumours and/or their treatment. The aim of this study was to examine the effect of GH replacement on growth/recurrence of non-anterior pituitary parasellar tumours.Methods: Fifty consecutive patients (21 males; mean age 45.9) with severe AO-GHD (peak seru...